APAvani Parikh

Avani Parikh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Avani Parikh has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeting Adaptive and Innate Immune Responses with Covalent Aptamers

    by Savannah Albright, Avani Parikh, Mary Cacace, Carolyn Rosenblum, Michael Dorogan, Jason Lohmueller, Alexander Deiters

    Covalent aptamers have recently found initial success as tools for fast and selective transfer of labels to target proteins. Here, aptamers targeting protein tyrosine kinase 7 (PTK7) and the mesenchymal-epithelial transition factor (cMet) were functionalized with electrophiles capable of covalently transferring small-molecule immune recruiters. Capitalizing on biotin transfer, aptamers were utilized to trigger activation of universal anti-biotin chimeric antigen receptor (CAR) T cells resulting in selective lysis of PTK7- and cMet-positive cells. Additionally, a cleavable electrophile of 2,4-dinitrophenyl (DNP) hapten transfer was synthesized and utilized for the selective modification of cell surface PTK7 and cMet. The DNP modification elicited the selective activation of complement-dependent cytotoxicity (CDC). These results demonstrate the potential of covalent aptamers as immune-activating and cancer-cell-killing agents.

  • Open Access

    Conditional Control of Benzylguanine Reaction with the Self-Labeling SNAP-tag Protein

    by Steven E. Caldwell, Isabella R. Demyan, Gianna N. Falcone, Avani Parikh, Jason Lohmueller, Alexander Deiters

    SNAP-tag, a mutant of the O6-alkylguanine-DNA-alkyltransferase, self-labels by reacting with benzylguanine (BG) substrates, thereby forming a thioether bond. SNAP-tag has been genetically fused to a wide range of proteins of interest in order to covalently modify them. In the context of both diagnostic and therapeutic applications, as well as use as a biological recording device, precise control in a spatial and temporal fashion over the covalent bond-forming reaction is desired to direct inputs, readouts, or therapeutic actions to specific locations, at specific time points, in cells and organisms. Here, we introduce a comprehensive suite of six caged BG molecules: one light-triggered and five others that can be activated through various chemical and biochemical stimuli, such as small molecules, transition metal catalysts, reactive oxygen species, and enzymes. These molecules are unable to react with SNAP-tag until the trigger is present, which leads to near complete SNAP-tag conjugation, as illustrated both in biochemical assays and on human cell surfaces. This approach holds promise for targeted therapeutic assembly at disease sites, offering the potential to reduce off-target effects and toxicity through precise trigger titration.


  • Open Access

    Conditional Control of Universal CAR T Cells by Cleavable OFF-Switch Adaptors

    by Michael Kvorjak, Elisa Ruffo, Yaniv Tivon, Victor So, Avani Parikh, Alexander Deiters, Jason Lohmueller

    As living drugs, engineered T cell therapies are revolutionizing disease treatment with their unique functional capabilities. However, they suffer from limitations of potentially unpredictable behavior, toxicities, and nontraditional pharmacokinetics. Engineering conditional control mechanisms responsive to tractable stimuli such as small molecules or light is thus highly desirable. We and others previously developed "universal" chimeric antigen receptors (CARs) that interact with coadministered antibody adaptors to direct target cell killing and T cell activation. Universal CARs are of high therapeutic interest due to their ability to simultaneously target multiple antigens on the same disease or different diseases by combining with adaptors to different antigens. Here, we further enhance the programmability and potential safety of universal CAR T cells by engineering OFF-switch adaptors that can conditionally control CAR activity, including T cell activation, target cell lysis, and transgene expression, in response to a small molecule or light stimulus. Moreover, in adaptor combination assays, OFF-switch adaptors were capable of orthogonal conditional targeting of multiple antigens simultaneously, following Boolean logic. OFF-switch adaptors represent a robust new approach for the precision targeting of universal CAR T cells with potential for enhanced safety.


  • Open Access

    Conditional control of universal CAR T cells by cleavable OFF-switch adaptors

    by Michael Kvorjak, Elisa Ruffo, Yaniv Tivon, Victor So, Avani B. Parikh, Alexander Deiters, Jason Lohmueller

    As living drugs, engineered T cell therapies are revolutionizing disease treatment with their unique functional capabilities. However, they suffer from limitations of potentially unpredictable behavior, toxicities, and non-traditional pharmacokinetics. Engineering conditional control mechanisms responsive to tractable stimuli such as small molecules or light is thus highly desirable. We and others previously developed “universal” chimeric antigen receptors (CARs) that interact with co-administered antibody adaptors to direct target cell killing and T cell activation. Universal CARs are of high therapeutic interest due to their ability to simultaneously target multiple antigens on the same disease or different diseases by combining with adaptors to different antigens. Here, we further enhance the programmability and potential safety of universal CAR T cells by engineering OFF-switch adaptors that can conditionally control CAR activity, including T cell activation, target cell lysis, and transgene expression, in response to a small molecule or light stimulus. Moreover, in adaptor combination assays, OFF-switch adaptors were capable of orthogonal conditional targeting of multiple antigens simultaneously following Boolean logic. OFF-switch adaptors represent a robust new approach for precision targeting of universal CAR T cells with potential for enhanced safety.


  • Open Access

    Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting

    by Elisa Ruffo, Adam A. Butchy, Yaniv Tivon, Victor So, Michael Kvorjak, Avani Parikh, Eric L. Adams, Natasa Miskov-Zivanov, Olivera J. Finn, Alexander Deiters, et al.

    Chimeric antigen receptors (CARs) and synthetic Notch (synNotch) receptors are engineered cell-surface receptors that sense a target antigen and respond by activating T cell receptor signaling or a customized gene program, respectively. Here, to expand the targeting capabilities of these receptors, we develop “universal” receptor systems for which receptor specificity can be directed post-translationally via covalent attachment of a co-administered antibody bearing a benzylguanine (BG) motif. A SNAPtag self-labeling enzyme is genetically fused to the receptor and reacts with BG-conjugated antibodies for covalent assembly, programming antigen recognition. We demonstrate that activation of SNAP-CAR and SNAP-synNotch receptors can be successfully targeted by clinically relevant BG-conjugated antibodies, including anti-tumor activity of SNAP-CAR T cells in vivo in a human tumor xenograft mouse model. Finally, we develop a mathematical model to better define the parameters affecting universal receptor signaling. SNAP receptors provide a powerful strategy to post-translationally reprogram the targeting specificity of engineered cells.